Lovelace Biomedical, a not-for-profit research organization which offers inhalation toxicology and other services for inhaled drug development, has announced the appointment of Larry Mallis as Director of Bioanalytical Operations.
Mallis was most recently Director of Bioanalytical Services as Frontage Laboratories and was previously Director of Scientific Services at Critical Path Services. He also worked in drug discovery for more than 20 years at a number of companies, including Bristol-Myers Squibb, Magainin Pharmaceuticals, Wyeth Research and Merck.
The company said, “The addition of Dr. Mallis to Lovelace Biomedical’s team is a significant milestone in our multi-year commitment to expanding capabilities, capacity and expertise in bioanalysis and bioanalytical chemistry. Along with key hires, Lovelace has invested in personnel, instrumentation and facilities to support both small molecules and biologics.”
According to Lovelace, the company has renovated more than 5,000 sq ft of laboratory space as part of its ongoing expansion.
Read the Lovelace Biomedical announcement.
